Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line

Dr Lal Pathlabs, India’s largest diagnostic chain, posted a 27 percent dip in consolidated net profit to Rs 62.1 crore in Q4FY22, as against a Rs 85 crore PAT in the year before period.

The stock price dipped by almost 1 percent on the NSE to Rs 2185 apiece.

Its operating revenue increased by 12.7 percent during the quarter to Rs 485.5 crore. Covid19 and allied segments contributed roughly 13.6 percent to the Q4 revenue. For the full year 2021-22, Dr Lal posted a PAT of Rs 350 crore as against Rs 296 crore in the previous fiscal, and its